Analysts think GYRE stock price could increase by 195%
Apr 06, 2025, 11:25 AM
35.02%
What does GYRE do
Gyre Therapeutics, a San Diego-based biopharmaceutical company with 593 employees, focuses on developing F351 for treating NASH-associated fibrosis and has a pipeline through its indirect interest in Gyre Pharmaceuticals. The company went public on April 12, 2006, and also offers the drug ETUARY.
3 analysts think GYRE stock price will increase by 194.58%. The current median analyst target is $20.40 compared to a current stock price of $6.92. The lowest analysts target is $20.20 and the highest analyst target is $21.00.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
